Trials / Terminated
TerminatedNCT04541485
To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)
Phase I Study to Evaluate the Safety, Tolerability, and Pharmacodynamics (PD) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in COVID-19 Patients
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to assess the safety and tolerability of single doses of DWRX2003 in COVID-19 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DWRX2003 | Intramuscularly injection at pre-defined injection sites |
| DRUG | Placebo | Intramuscularly injection at pre-defined injection sites |
Timeline
- Start date
- 2020-12-04
- Primary completion
- 2021-03-03
- Completion
- 2021-03-23
- First posted
- 2020-09-09
- Last updated
- 2021-09-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04541485. Inclusion in this directory is not an endorsement.